Septerna's GPCR platform shows promise, but execution risks, funding needs, and competition suggest caution. Click here to ...

Novo Nordisk CEO's ouster signals stiff competition in the obesity market, getting dominated by Eli Lilly, with Roche, ...

In a press release announcing the move, Novo Nordisk cited market challenges and its declining share price in a press release ...

For those preferring a drug-free approach to weight loss, research shows that certain nutrients and dietary strategies can naturally mimic the effects of semaglutides.

Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, ...

The common theme at the maker of Wegovy and at UnitedHealth may be investors' sudden awareness of cost-cutting pressure.

Ozempic-maker Novo Nordisk on Friday ousted its CEO Lars Fruergaard Jorgensen over concerns the company is losing its ...

ORLANDO -- Fracture risk may be higher after bariatric surgery than after treatment with weight-loss drugs, propensity-score ...

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes ...

Investors may get a second bite at the apple, and a second chance to buy this GLP-1 drug leader at a discount price.

People on GLP-1 medication seem to be adding more protein to their diets, further increasing demand for chicken and beef at a ...

The company behind the weight loss sensation that transformed bodies and bank accounts across America just showed its own CEO ...